Clovis down after discontinuing rucaparib bladder cancer trial

Clovis was off $3.08 (13%) to $20.40 in after-hours trading Friday after the company disclosed that it discontinued the Phase II ATLAS trial of Rubraca (rucaparib) as monotherapy to treat locally advanced unresectable or metastatic urothelial carcinoma.